Read our latest news, and find more about us and our portfolio companies.
26th April 2023
Investors' Chronicle
A biotech stock at an unwarranted discount
25th April 2023
Shares Magazine
Arix Bioscience narrows annual loss but net asset value decreases
21st February 2023
Labiotech
Disc Medicine raises $62.5M for hematology programs
End Points
With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital
9th February 2023
Bargain Shares 2023
27th January 2023
Technology Networks
New Approaches for Cancer Therapies: Targeting the DNA Damage Response
9th January 2023
The Pharma Letter
Ensoma Announces Financing and Acquisition
6th January 2023
Ensoma Acquiring Twelve Bio
EndPoints
On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M
16th October 2022
MedCity News
Cancer drug biotech Enliven shifts to reverse to move forward as a public company
14th October 2022
BioCentury
Oct. 14 Quick Takes
3rd October 2022
Endpoints
#AAO22: On the heels of PhIII launch, Aura details second administration route of its ocular oncology drug
17th August 2022
Business Weekly
Artios Pharma trials new breast cancer treatment
12th August 2022
Arix Bioscience NAV falls; portfolio firm Disc to merge with Gemini
A Ben Graham recovery play
10th August 2022
Disc Medicine goes public in reverse merger with struggling Gemini Therapeutics
Fierce Biotech
Disc inks Gemini merger, secures cash from starry VC syndicate to advance ex-AbbVie, Roche drugs
27th July 2022
The Economist
The life-sciences industry is a jewel in Britain’s economy
13th June 2022
The Killer 50 Profiles
10th May 2022
Bargain Shares: A Ben Graham contrarian value play
21st April 2022
Utah Business
Sorriso Pharmaceuticals is creating the first orally-delivered anti-inflammatory drug for patients with IBD
1st April 2022
The Herald Scotland
New ovarian cancer study to probe causes of PARP inhibitor resistance
3rd March 2022
Targeted Oncology
FDA Grants Fast Track Designation to HPN217 for R/R Multiple Myeloma
22nd December 2021
Finsmes
Sorriso Pharmaceuticals Raises $31M in Series A Funding
Citybiz
NEA Co-Leads $31 Million Series A in Sorriso Pharmaceuticals
Biotech vets jump on board a startup, raise cash and take aim at the clinic with anti-inflammatory drugs
16th December 2021
Health Investor
Depixus raises €30.6m in Series A financing
15th December 2021
European Biotechnology
Genome Web
Nucleic Acid Analysis Startup Depixus Raises €30.6M in Series A Financing
9th November 2021
Bargain shares: On the M&A beat
2nd November 2021
Intracellular targets, eye cancer therapy and light-activated skincare: Here's the latest on biotech IPOs
11th October 2021
Investors Chronicle
Bargain shares: A heavily oversold biotech value recovery play
6th September 2021
PharmaLive
Investors Hand Disc Medicine $90 Million To Control Hematological Diseases
Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup
Disc Medicine nabs $90M for blood disease pipeline, new Roche asset
29th July 2021
BioWorld
Artios’ $153M series C to expand DDR platform beyond synthetic lethality
Novartis partner Artios bags megaround to drive clinical work on DNA damage repair factors
Artios raises $153M to fund DNA damage repair clinical trials
17th May 2021
In Vivo
In Vivo's 2021 Rising Leaders: Recognizing Talent Across The Life Sciences
10th May 2021
The Times
Inside Track: Amplyx's Ciara Kennedy is on the boil after fungi-fighting Pfizer buyout
6th May 2021
Amplyx laid out a promising path to a pivotal antifungal drug trial, and now Pfizer is scooping it all up in a buyout
Pfizer buys Amplyx to grow infectious disease pipeline
9th April 2021
Pharma Times
Artios, Novartis form cancer therapies collaboration
Novartis taps Artios for targets to enhance radioligand drugs
Five Investment Company Bargains
30th March 2021
The Business Journals
Oncology startup to double size with $152M
10th March 2021
INVESTORS CHRONICLE
Clean up with two deep value plays
Scrip
New Company Twelve Bio Aims To Improve On CRISPR Gene-Editing Tech
9th March 2021
Vox Markets
Arix Bioscience reports FY20NAV up 62%
PROACTIVE
Arix Bioscience sees sharp uplift in net asset value in 2020
ASKTRADERS
Arix Bioscience Shares Rally 5.4% as Net Asset Value Surges on VelosBio Sale to Merck
EVENING STANDARD
Arix Bioscience sees value rocket 62% as UK biotech scene booms
1st March 2021
C&EN
The Fight Against Fungi
5th February 2021
Bargain shares for 2021
3rd February 2021
LSX Leaders
LSX London 2021 Biotech - Accelerating Innovation Through Early-Stage Investment
26th January 2021
Pharmaphorum
Biden administration – What can the healthcare industry expect?
21st January 2021
OneNucleus
Around the World in Venture Capital
6th January 2021
Citywire
David Stevenson: This is my portfolio for 2021
11th December 2020
Investors chronicle
Exploit Arix Bioscience’s huge margin of safety
Arix Bioscience portfolio company Atox Bio announces FDA acceptance of its NDA for ‘flesh-eating’ disorder treatment
10th December 2020
Financial Times
Why Tech trend is worth following beyond 2020
3rd December 2020
Arix Bioscience shares rise on collaboration deal with Merck KGaA
Proactive
Arix Bioscience portfolio company Artios signs cancer collaboration deal with Merck KGaA worth up to $7bn
12th November 2020
Latest takeovers focus on two specific groups of stocks
23rd September 2020
Deal-Making During A Pandemic And 2021 Expectations